Books
in black and white
Main menu
Share a book About us Home
Books
Biology Business Chemistry Computers Culture Economics Fiction Games Guide History Management Mathematical Medicine Mental Fitnes Physics Psychology Scince Sport Technics
Ads

biopharmaceuticals biochemistry and biotecnology - Walsh G.

Walsh G. biopharmaceuticals biochemistry and biotecnology - John Wiley & Sons, 2003. - 572 p.
ISBN 0-470-84327-6
Download (direct link): biochemistryandbiotechnology2003.pdf
Previous << 1 .. 51 52 53 54 55 56 < 57 > 58 59 60 61 62 63 .. 292 >> Next

Askari, F. (2003). Beyond the Genomeó The Proteomics Revolution. Prometheus, Frome, UK.
Crommelin, D. (2002). Pharmaceutical Biotechnology. Routledge, London.
De Jong, M. (1998). FAQs on EU Pharmaceutical Regulatory Affairs. Brookwood Medical, Richmond, UK.
Desalli, R. (2002). The Genomics Revolution. Joseph Henry Press.
Ferraiolo, B. (1992). Protein Pharmacokinetics and Metabolism. Plenum, New York.
Giffels, J. (1996). Clinical Trials. Demos Medical, London.
90 BIOPHARMACEUTICALS
Goldberg, R. (2001). Pharmaceutical Medicine, Biotechnology and European Patent Law. Cambridge University Press, Cambridge.
Grindley, J. & Ogden, J. (2000). Understanding Biopharmaceuticals. Manufacturing and Regulatory Issues. Interpharm, Denver, CO.
Hunt, S. (2000). Functional Genomics. Oxford University Press, Oxford.
Knight, H. (2001). Patent Strategy. Wiley, Chichester.
Krogsgaard, L. (2002). Textbook of Drug Design and Discovery. Taylor and Francis, London.
McNally, E. (Ed), (2000). Protein Formulation and Delivery. Marcel Dekker, New York.
Oxender, D. & Post, L. (1999). Novel Therapeutics from Modern Biotechnology. Springer-Verlag, Berlin.
Pennington, S. (2000). Proteomics. BIOS Scientific, Oxford.
Poste, G. (1999). The Impact of Genomics on Healthcare. Royal Society of Medicine Press, London.
Scolnick, E. (2001). Drug Discovery and Design. Academic Press, London.
Venter, J. (2000). From Genome to Therapy. Wiley, Chichester.
Articles
Clinical trials and regulatory authorities
Beatrice, M. (1997). FDA regulatory reform. Curr. Opin. Biotechnol. 18(3), 370-378.
Crooke, S. (1995). Comprehensive reform of the new drug regulatory process. Bio/Technology 13, 25-29.
Graffeo, A. (1994). The doís and doníts of preclinical development. Bio/Technology 12, 865.
Helms, P. (2002). Real world pragmatic clinical trials: what are they and what do they tell us? Pediat. Allergy Immunol. 13(1), 4-9.
Jefferys, D. & Jones, K. (1995). EMEA and the new pharmaceutical procedures for Europe. Eur. J. Clin. Pharmacol. 47, 471-476.
Kaitin, K. (1997). FDA reform: setting the stage for efforts to reform the agency. Drug Inf. J. 31, 27-33.
Kessler, D. & Feiden, K. (1995). Faster evaluation of vital drugs. Sci. Am. March, 26-32.
Lubiniecki, A. (1997). Potential influence of international harmonization of pharmaceutical regulations on biopharmaceutical development. Curr. Opin. Biotechnol. 8(3), 350-356.
Pignatti, F et al. (2002). Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology.
Crit. Rev. Oncol. Haematol. 42(2), 123-135.
Sauer, F. (1997). A new and fast drug approval system in Europe. Drug Inf. J. 31, 1-6.
Walsh, G. (1999). Drug approval in Europe. Nature Biotechnol. 17, 237-240
Patenting
Allison, J. & Lemley, M. (2002). The growing complexity of the United States patenting system. Boston Univ. Law Rev. 82(1), 77-144.
Barton, J. (1991). Patenting life. Sci. Am. March, 18-24.
Berks, A. (1994). Patent information in biotechnology. Trends Biotechnol. 12, 352-364.
Crespi, R. (1993). Biotechnological inventions and the patent law: outstanding issues. Biotechnol. Genet. Eng. Rev. 11, 229-261.
Crespi, R. (1994). Protecting biotechnological inventions. Trends Biotechnol. 12, 395-397.
Johnson, E. (1996). A benchside guide to patents and patenting. Nature Biotechnol. 14, 288-291.
Orr, R. & OíNeill, C. (2000). Patent review: therapeutic applications of antisense oligonucleotides, 1999-2000. Curr. Opin. Mol. Therapeut. 2(3), 325-331.
Drug development
Bugg, C. et al. (1993). Drugs by design. Sci. Am. December, 92-98.
Cox, P. & Balick, M. (1994). The ethanobotanical approach to drug discovery. Sci. Am. June, 60-65.
Drews, J. (2000). Drug discovery: a historical perspective. Science 287(5460), 1960-1964.
Dykes, C. (1996). Genes, disease and medicine. Br. J. Clin. Pharmacol. 42(6), 683-695.
Ecker, D. & Crooke, S. (1995). Combinatorial drug discovery: which methods will produce greatest value? Bio/ Technology 13, 351-359.
Geisow, M. J. (1991) Characterizing recombinant proteins. Bio/Technology, 9(10), 921-922.
Hodgson, J. (1993). Pharmaceutical screening: from off the wall to off the shelf. Bio/Technol. 11, 683-688.
Lowman, H. (1997). Bacteriophage display and discovery of peptide leads for drug development. Ann. Rev. Biophys. Biomol. Struct. 26, 401-424.
THE DRUG DEVELOPMENT PROCESS 91
Medynski, D. (1994). Synthetic peptide combinatorial libraries. Bio/Technology 12, 709-710.
Saragovi, H. et al. (1992). Loops and secondary structure mimetics: development and applications in basic science and rational drug discovery. Bio/Technology 10, 773-777.
Scicinski, J. (1995). Chemical libraries in drug discovery. Trends Biotechnol 13, 246-247.
Genomics, proteomics and related technologies
Baba, Y. (2001). Development of novel biomedicine based on genome science. Eur. J. Pharmaceut. Sci. 13(1), 3-4. Brenner, S. (2001). A tour of structural genomics. Nature Rev. Genet. 2(10), 801-809.
Previous << 1 .. 51 52 53 54 55 56 < 57 > 58 59 60 61 62 63 .. 292 >> Next